Conazole fungicides inhibit Leydig cell testosterone secretion and androgen receptor activation in vitro  by Roelofs, Maarke J.E. et al.
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a  b  s  t  r  a  c  t
Conazole  fungicides  are  widely  used  in agriculture  despite  their  suspected  endocrine  dis-
rupting  properties.  In this  study,  the  potential  (anti-)androgenic  effects  of ten  conazoles
were  assessed  and  mutually  compared  with  existing  data.  Effects  of  cyproconazole  (CYPRO),
ﬂuconazole  (FLUC),  ﬂusilazole  (FLUS),  hexaconazole  (HEXA),  myconazole  (MYC),  pencona-
zole (PEN),  prochloraz  (PRO),  tebuconazole  (TEBU),  triadimefon  (TRIA),  and  triticonazole
(TRIT)  were  examined  using  murine  Leydig  (MA-10)  cells  and  human  T47D-ARE  cells  sta-
bly transfected  with  an androgen  responsive  element  and  a ﬁreﬂy  luciferase  reporter  gene.
Six  conazoles  caused  a decrease  in  basal  testosterone  (T)  secretion  by MA-10  cells  varying
from 61%  up  to  12% compared  to vehicle-treated  control.  T secretion  was concentration-
dependently  inhibited  after exposure  of  MA-10  cells  to several  concentrations  of  FLUS
(IC50 =  12.4  M)  or TEBU  (IC50 =  2.4 M)  in  combination  with  LH.  The  expression  of steroido-
genic  and  cholesterol  biosynthesis  genes  was  not  changed  by conazole  exposure.  Also,  there
were no changes  in  reactive  oxygen  species  (ROS)  formation  that  could  explain  the  altered
T secretion  after  exposure  to conazoles.  Nine  conazoles  decreased  T-induced  AR  activationriadimefon (PubChem CID: 39385)
riticonazole (PubChem CID: 6537961)
eywords:
ndrogen receptor (AR)
onazole  fungicides
(IC50s ranging  from  10.7  to 71.5  M)  and  effect  potencies  (REPs)  were  calculated  relative
to  the  known  AR  antagonist  ﬂutamide  (FLUT).  FLUC  had  no effect  on AR  activation  by T.
FLUS was  the  most  potent  (REP  = 3.61)  and  MYC the  least  potent  (REP  =  0.03)  AR  antago-
nist.  All  other  conazoles  had  a comparable  REP  from  0.12  to 0.38.  Our  results  show  distinct
in  vitro  anti-androgenic  effects  of  several  conazole  fungicides  arising  from  two  mecha-
nisms:  inhibition  of  T secretion  and  AR  antagonism,  suggesting  potential  testicular  toxic
Abbreviations: 3-HSD1, 3-hydroxysteroid dehydrogenase type 1; 17-HSD3, 17-hydroxysteroid dehydrogenase type 3; AR, androgen receptor;
MR,  benchmark response; cAMP, 8-bromoadenosine 3′ ,5′-cyclic monophosphate; CHO cells, Chinese hamster ovary cells; Cyp11A1, cytochrome P450
nzyme  11A; Cyp17, cytochrome P450 enzyme 17; CYP19, cytochrome P450 enzyme 19 (aromatase); CYP51, cytochrome P450 enzyme 51/lanosterol 14-
emethylase;  CYPRO, cyproconazole; DMEM,  Dulbecco’s Modiﬁed Eagle Medium; EC50, half maximal effective concentration; EDCs, endocrine disrupting
hemicals;  FLUC, ﬂuconazole; FLUS, ﬂusilazole; FLUT, ﬂutamide; FP, forward primer; FSH(R), follicle-stimulating hormone (receptor); H295R, human
drenocortical  carcinoma cells; HEXA, hexaconazole; HMG-CoA red, HMG-CoA reductase; HSD(s), hydroxysteroid dehydrogenase(s); IC50, half maximal
nhibitory  concentration; LH(R), luteinizing hormone (receptor); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MYC, myclobu-
anil;  NCBI, National Center for Biotechnology Information; PBS, phosphate-buffered saline; PEN, penconazole; Por, cytochrome P450 oxidoreductase;
RO,  prochloraz; REP, relative effect potency; RIA, radioimmunoassay; ROS, reactive oxygen species; RP, reverse primer; RT-qPCR, real time quantitative
olymerase  chain reaction; StAR, steroidogenic acute regulatory protein; T, testosterone; TEBU, tebuconazole; TRIA, triadimefon; TRIT, triticonazole.
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Endocrine disrupting chemicals (EDCs)
MA-10 Leydig cells
Spermatogenesis
Testosterone  (T)
effects.  These  effects  warrant  further  mechanistic  investigation  and  clearly  show  the  need
for  accurate  exposure  data  in  order  to perform  proper  (human)  risk  assessment  of  this  class
of  compounds.
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1. Introduction
Several studies indicate a global decline in human
male fertility over the past decades due to poor semen
quality, a suggested decline in sperm count, and low-
ered testosterone levels in men  [1–3]. Furthermore, an
overall  increase up to 12% in assisted reproductive treat-
ments  is observed in Scandinavian countries as well
as  Switzerland, The Netherlands, and United Kingdom
over the past years [4]. In 20% of infertile couples this
infertility was attributed to male factors solely and in
another 30–40% male factors are conducive [5]. Exposure to
environmental chemicals, including endocrine disrupting
chemicals (EDCs), is often suggested to be an impor-
tant contributing factor to these trends in male infertility
[6,7].
Among the list of suggested EDCs pesticides are strongly
represented [8]. Conazoles are a class of azole-based fungi-
cides  that are widely used as pesticides in the cultivation
of crops [9] but also as human and veterinary pharma-
ceuticals for the treatment of oropharyngeal, vaginal, as
well  as systemic candida and mycosis infections [10].
These compounds decrease fungal membrane integrity by
inhibiting  the cytochrome P450 enzyme lanosterol 14-
demethylase (CYP51), which is essential for ergosterol
biosynthesis and maintaining proper membrane ﬂuidity
and  permeability in fungi [9]. Besides fungal CYP51, cona-
zoles  also target CYP51 of mammals and other vertebrates,
which catalyzes the formation of the cholesterol precursor
zymosterol [11,12]. Conazoles are known to have in vivo
endocrine disruptive effects in mammals. For instance,
demasculinization of male rat fetuses occurred upon in
utero  exposure to several conazoles [13]. Yet, it remains to
be  investigated to what extent the known effects of a few
tested  conazoles are reminiscent for the whole group of
conazoles.
The  testicular microenvironment is pivotal for mam-
malian steroidogenesis and intratesticular androgens are
required  for normal spermatogenesis [14]. In adult males,
spermatogenesis is driven by the gonadotropins luteiniz-
ing  hormone (LH) and follicle-stimulating hormone (FSH).
Via  activation of the LH receptor (LHR), LH stimulates
testosterone (T) production in the Leydig cells. Testicular
production of T in interstitial Leydig cells is prerequisite for
proper  spermatogenesis and involves multiple steroido-
genic enzymes, e.g. steroidogenic acute regulatory protein
(StAR),  cytochrome P450 cholesterol side-chain cleavage
enzyme (CYP11A1), 17-hydroxylase/20-lyase (CYP17A1),
3-  and 17-hydroxysteroid dehydrogenase (3-HSD and
17-HSD, respectively) [15]. Subsequently, testosterone
binds to the androgen receptor (AR) present in Sertoli cells,
which,  in combination with FSH binding to the FSH recep-
tor  (FSHR), stimulates the progression of spermatogenesis
[16].ished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under
D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Conazoles are known to inhibit the steroidogenic
enzyme aromatase (CYP19) in several tissues and cell
lines,  which is involved in the conversion of androgens to
estrogens  [9,10,17–19]. Conazoles also cause catalytic inhi-
bition  of the CYP17 enzyme, responsible for the conversion
of  pregnenolone and progesterone to androgen precur-
sors, in the human adrenocortical carcinoma H295R cell
line  and porcine adrenal cortex microsomes [20]. Previ-
ous  work in H295R cells showed a decrease in T secretion
after exposure to econazole, epoxiconazole, ketoconazole,
miconazole, prochloraz, propiconazole, and tebuconazole
[10]. In combination with the drop in T secretion, an
increase in progesterone biosynthesis was  seen after expo-
sure  to prochloraz, indicating that the role of the CYP17
enzyme is very important in this matter [21]. Further-
more, Cyp26A1, a crucial enzyme within in the retinol
metabolism pathway, seems to be a target for conazoles
in the zebraﬁsh embryo [12], an underlying mechanism for
developmental toxicity. Spermatogenesis is tightly regu-
lated  by several steroidogenic processes involving multiple
enzymatic conversions. The production of steroids by
conversion of cholesterol via a cascade of several (CYP)
enzymes is the ﬁrst and crucial step to initiate sperm
production, which makes it a vulnerable target for EDCs
interference.
In  spite of the large production and extensive usage of
many  conazoles, accurate data on human exposure lev-
els  are scarce. Besides occupational and pharmaceutical
exposure, individuals can also be exposed to conazoles
by environmental, food, resident, or bystander expo-
sure. This is supported by increasing concentrations of
conazole pesticides found in surface and waste waters
[22]. According to case reports on the risk assessment
of tebuconazole, conazoles are moderately and chron-
ically toxic to aquatic species. The environmental fate
route  is mainly via the soil, where it is persistent due to
its  elimination half-life of approximately 800 days [23].
Pesticide usage surveys performed in the UK show that
triazole usage has increased from 6.1 in 1990 to approx-
imately 16.4 million ha treated in 2011 [24]. Among the
conazoles, tebuconazole (2.5 million ha) is the most fre-
quently used conazole fungicide, followed by prochloraz
and cyproconazole (both 1.3 million ha), and then ﬂusila-
zole  and triticonazole (0.6 and 0.5 million ha, respectively).
Because of this extensive usage of conazoles, there is a
potential risk that humans and wildlife are frequently,
possibly chronically exposed to these compounds via
their  environment. The potential to affect steroid hor-
mone synthesis in combination with the likelihood of
frequent exposure make conazoles an important and rel-
evant  group of compounds to consider for effects on male
fertility.
In  this in vitro study, the effects of ten conazoles on
two  key male reproductive factors were assessed and
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Table 1
Overview of the ten selected conazoles used in this study, type of conazole, method of application, and structural formula (derived from MDL  ISISTM/Draw
2.5,  MDL  Information Systems, Inc., San Leandro, CA, USA).
Conazole Abbreviation Type Use Structure
Cyproconazole CYPRO Triazole Pesticide
Fluconazole FLUC Triazole Pharmaceutical
Flusilazole FLUS Triazole Pesticide
Hexaconazole HEXA Triazole Pesticide
Myclobutanil MYC  Triazole Pesticide
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Table  1 (Continued)
Conazole Abbreviation Type Use Structure
Penconazole PEN Triazole Pesticide
Prochloraz PRO Imidazole Pesticide
Tebuconazole TEBU Triazole Pesticide
Triadimefon TRIA Triazole Pesticide
Triticonazole TRIT Triazole Pesticidecompared, namely testicular steroidogenesis and AR
response. These conazoles were selected based on their
usage  as a fungicide for crop protection and included cypro-
conazole  (CYPRO), ﬂusilazole (FLUS), hexaconazole (HEXA),
myclobutanil (MYC), penconazole (PEN), prochloraz (PRO),
tebuconazole (TEBU), triadimefon (TRIA), and triticonazole
(TRIT) (Table 1). For comparison, we also included oneconazole  used as pharmaceutical, i.e. ﬂuconazole (FLUC;
Table  1). Effects on basal and LH-stimulated T secretion
and steroidogenic gene expression were studied in murine
MA-10  Leydig cells. A number of toxicants is also known
to  contribute to a decrease in sperm viability and motility
by  increasing ROS production in the testis and epididymis
[25]. Therefore, effects of conazoles on ROS formation in
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A-10 cells were determined as well. In addition, effects
n  AR activation were assessed in human T47D-ARE cells
tably  transfected with a luciferase reporter gene.
.  Materials and methods
.1.  Chemicals
The ten selected conazoles (Table 1) were purchased
rom Sigma–Aldrich Co. (Zwijndrecht, The Netherlands):
yproconazole (CYPRO; 99.8%, CAS# 94361-06-5), ﬂu-
onazole (FLUC; ≥98%, CAS# 86386-73-4), ﬂusilazole
FLUS; 99.8%, CAS# 85509-19-9), hexaconazole (HEXA;
9.7%, CAS# 79983-71-4), myclobutanil (MYC; 99.3%, CAS#
8671-89-0), penconazole (PEN; 99.1%, CAS# 66246-88-6),
rochloraz (PRO; 99.1%, CAS# 67747-09-5), tebucona-
ole (TEBU; 99.6%, CAS# 107534-96-3), triadimefon (TRIA;
9.7%,  CAS# 43121-43-3), and triticonazole (TRIT; 98.8%,
AS#  131983-72-7). SU10603 was a kind gift from Dr.
onora Cooper Eckhardt (Hovartis Pharmaceuticals Cor-
oration,  Summit, USA). Stock solutions were prepared in
MSO  resulting in a maximal solvent concentration of 0.1%
v/v) in the exposure medium.
.2. MA-10 Leydig cell culture
The  murine Leydig tumor cell line MA-10 was kindly
rovided by Dr. Mario Ascoli (University of Iowa, Iowa City,
A,  USA) [26]. Cells were cultured as described previously
y Dankers et al. [27]. In short, cells were grown in 1:1
ulbecco’s Modiﬁed Eagle Medium/F-12 nutrient mixture
Ham)  with phenol red (DMEM/F-12 1:1, #11320; Gibco,
ife  Technologies Europe BV, Bleiswijk, The Netherlands)
upplemented with 15% HyClone (#SH30068.03; Thermo
isher  Scientiﬁc, Waltham, MA,  USA), 2% HEPES [1 M]
#15630; Gibco), and 1% penicillin/streptomycin (#15140;
ibco) and maintained at 37 ◦C in a humidiﬁed atmosphere
95%) with 5% CO2. Cells were cultured twice weekly and
ulture  medium was refreshed 24 h prior to subculturing.
lasks and plates were coated at room temperature with
.1%  gelatin (Attachment Factor Protein; Gibco) 45 min
rior  to use.
.3.  Testosterone secretion assay
T secretion was assessed with MA-10 cells plated at a
ensity  of 2.0 × 105 cells/well in 24-well Plates 24 h prior
o  exposure. 8-Bromoadenosine 3′,5′-cyclic monophos-
hate (cAMP; [100 M])  induces the expression of genes
f  steroidogenic enzymes and was used as positive con-
rol.  SU10603 [1 M]  is a catalytic CYP17 enzyme inhibitor
28] and was used as a control for decreased T secre-
ion. For basal T measurements cells were exposed to
he  selected conazoles [10 M]  alone. Gonadotropin LH
10  ng/mL = 8.5 IU/mL) was used to stimulate the Leydig
ells  to produce T. To determine the effect of selected cona-
oles  on LH-induced T secretion, cells were exposed to a
ombination of LH (10 ng/mL) and SU10603 (0.05–1 M),
LUS  or TEBU (0.3–10 M).  After a 48-h exposure, medium
as collected and stored at −20 ◦C until further use.
 measurements in the media were performed with
 commercially available T radioimmunoassay (T RIA)ports 1 (2014) 271–283 275
kit  according to the manufacturer’s instructions (#DSL-
4900; analytical sensitivity = 0.18 pg/mL; Beckman Coulter
GmbH,  Krefeld, Germany).
2.4.  Gene expression
For  gene expression experiments, MA-10 cells were
plated at a density of 6.0 × 105 cells/well in 12-well Plates
24  h prior to exposure. Cells were exposed for 6 h to
CYPRO, FLUS, PRO, TEBU [10 M],  and the positive con-
trol  cAMP [100 M].  Total RNA was  isolated from exposed
MA-10 cells by chloroform-phenol extraction using RNA
InstaPure according to the manufacturer’s instruction
(Eurogentec, Liège, Belgium). Purity and concentration of
isolated  RNA was  determined spectrophotometrically at
absorbance  wavelengths of 230, 260, and 280 nm using
a  NanoDrop2000 Spectrophotometer (Thermo Fisher Sci-
entiﬁc,  Waltham, MA,  USA). RNA samples were diluted to
a  concentration of 66.7 g/mL and stored at −80 ◦C until
further use. cDNA was  prepared using the iScript cDNA
synthesis kit (Bio-Rad Laboratories Inc., Veenendaal, The
Netherlands) and synthesized cDNA was  diluted to the
appropriate concentration for each primer pair (Supple-
mentary Table 1). Real time quantitative polymerase chain
reaction  (RT-qPCR) was  performed with a mixture contain-
ing  7.5 L iQ SYBR green supermix (Bio-Rad Laboratories
Inc., Veenendaal, The Netherlands), 0.6 L forward primer
(FP)  and 0.6 L reversed primer (RP) [each 10 M],  0.3 L
RNAse free water, and 6 L of diluted cDNA.
Supplementary Table 1 related to this article can
be found, in the online version, at doi:10.1016/j.toxrep.
2014.05.006.
The expression of ﬁve steroidogenic genes was  studied:
steroidogenic acute regulatory protein (StAR), cytochrome
P450 enzyme 11A1 (Cyp11A1), cytochrome P450 enzyme
17  (Cyp17A1), 3-hydroxysteroid dehydrogenase type 1
(3-HSD1),  and 17-hydroxysteroid dehydrogenase type
3  (17-HSD3). Also, the expression of three cholesterol
biosynthesis genes was studied: cytochrome P450 enzyme
51  (Cyp51), HMG-CoA reductase (HMG-CoA red), and
cytochrome P450 oxidoreductase (Por). -Actin was  used
as  a reference gene. Sequences of the primer pairs used
are  depicted in Supplementary Table 1. All primers span
an  exon–exon junction to ensure mRNA ampliﬁcation only
and  were run through National Center for Biotechnol-
ogy Information (NCBI) Blast (nucleotide non-redundant
database) to conﬁrm speciﬁcity. Efﬁciency was determined
and  was for all primer pairs between 90 and 110%. The
mixtures were placed in the CFX ConnectTM (Bio-Rad Labo-
ratories Inc.) and ﬁrstly heated till 95 ◦C for 3 min, following
40  cycles of denaturation at 95 ◦C for 15 s and anneal-
ing/extension at 60 ◦C for 45 s. Subsequently, a melt curve
was  run to ensure the exclusion of primer dimers and other
non-speciﬁc products formed during the RT-qPCR. Gene
expression of each sample was  expressed as threshold cycle
(Ct),  normalized to the reference gene -actin (Ct), and
fold  induction relative to the DMSO control was calculated.2.5.  Reactive oxygen species assay
ROS production in MA-10 cells was  assessed using the
ﬂuorescent dye H2-DCFDA (#D-399; Gibco). MA-10 cells
ology R276 M.J.E. Roelofs et al. / Toxic
were plated at a density of 7.5 × 104 cells/well in 96-well
Plates 24 h prior to addition of the ﬂuorescent dye. Cells
were  loaded with H2-DCFDA [10 M]  for 2 h prior to expo-
sure  at 37 ◦C. After loading, the dye was removed and
cells were washed twice with warm PBS. Subsequently,
cells were exposed to the ten selected conazoles at con-
centrations ranging from 0.01 to 100 M for up to 48 h.
Dye  and exposure solutions were prepared in serum-
free assay medium (DMEM/F-12 1:1 without phenol red,
#11039;  Gibco). Fluorescence was measured spectropho-
tometrically at wavelengths of 485/530 nm (Inﬁnite M200
microplate; Tecan Group Ltd., Männedorf, Germany) at T = 0
(to  determine the basal background level), 1, 24, and 48 h
of  exposure. As a positive control for oxidative stress at the
short  time point (T = 1 h) H2O2 [20 mM]  (hydrogen perox-
ide  30%, #107209; Merck KGaA, Darmstadt, Germany) was
used,  for the longer time points (T = 24 and 48 h) rotenone
[100 M]  (#45656; Sigma–Aldrich Co.) was used. As non-
exposed control cells show a basal ROS production over
time,  data are expressed as average percentage compared
to  the time-matched control values.
2.6. T47D-ARE cell culture
The  human breast cancer cell line T47D-ARE was
kindly provided by Prof. Dr. Michael Denison (University
of  California, Davis, CA, USA). T47D-ARE cells are trans-
fected with an androgen responsive element with a ﬁreﬂy
luciferase reporter gene [29]. Cells were grown in Dul-
becco’s Modiﬁed Eagle Medium with phenol red containing
4.5  g/L d-glucose, l-glutamine, and pyruvate with phe-
nol  red (DMEM, #41966; Gibco) supplemented with 10%
fetal  bovine serum (FBS, #10270; Gibco) and 1% peni-
cillin/streptomycin (#15140; Gibco) and maintained at
37 ◦C in a humidiﬁed atmosphere (95%) with 5% CO2. Cells
were  sub-cultured twice every week.
2.7. Androgen receptor reporter gene assay
Culture medium of T47D-ARE cell was replaced by
assay medium 72 h prior to seeding. Assay medium was
composed of Dulbecco’s Modiﬁed Eagle Medium without
phenol red containing 4.5 g/L d-glucose (DMEM, #31053;
Gibco) supplemented with 10% HyClone (#SH30068.03;
Thermo Fisher Scientiﬁc), 1% l-glutamine [200 mM]
(#25030; Gibco), 1% sodium pyruvate [100 mM]  (#11360;
Gibco), and 1% penicillin/streptomycin (#15140; Gibco).
Cells  were seeded at a density of 4.0 × 105 cells/well in
white 96-well plates with a clear ﬂat bottom (#655098;
Greiner Bio-One, Alphen aan den Rijn, The Netherlands)
48 h prior to exposure. AR activation was determined by
measuring the luciferase reaction luminescence. The lumi-
nescent  signal evoked by the luciferase reaction was mea-
sured  as relative luminescence units (RLU) of T47D-ARE
cells exposed to concentration curves ranging from 100 pM
to  100 M of the ten selected conazoles. Exposures were
performed in the presence or absence of EC50 of T [20 nM].
The  known AR antagonist ﬂutamide (FLUT) was  used as
positive  control for AR antagonism [30]. After a 24-h expo-
sure,  cells were washed with warm phosphate-bufferedeports 1 (2014) 271–283
saline solution (PBS, diluted 1:10 with sterile water,
#14200; Gibco) and incubated with 1x luciferase cell cul-
ture  lysis reagent (pH = 7.8; #E1531; Promega, Madison,
WI,  USA) for 30 min. Subsequently, luciferase activity was
measured by addition of reagent mix  (LUMIstar Galaxy
luminometer, BMG  Labtech GmbH, Ortenberg, Germany).
The  reagent mix  was composed of tricine [20 mM]
(#T5816; Sigma–Aldrich Co.), (MgCO3)4Mg(OH)2·5H2O
[1.07  mM]  (#227668; Sigma–Aldrich Co.), MgSO4·7H2O
[2.67  mM]  (#63138; Sigma–Aldrich Co.), EDTA [0.1 mM]
(#ED2SS; Sigma–Aldrich Co.), DTT [33.3 mM]  (#D9779;
Sigma–Aldrich Co.), coenzyme A [261 M]  (#A2181;
Sigma–Aldrich Co.), luciferin [470 M]  (#1605; Promega),
and ATP [530 M]  (#10127531001; Roche Diagnostics Cor-
poration,  Indianapolis, IN, USA) dissolved in Milli-Q water
(pH  = 7.8).
For FLUT and each conazole exposure the half max-
imal inhibitory concentration (IC50) of AR activation
was  derived from concentration–response curves using a
sigmoidal  dose–response nonlinear regression curve ﬁt
with  variable slope following the formula (1):
y = E0 +
(
(Emax × Xn)
bn + Xn
)
. (1)
In the above Hill equation, y is the dependent variable
(AR response), X the independent variable (exposure con-
centration), E0 the estimated background response level,
Emax the maximum response, b the computed half maxi-
mal  inhibitory concentration of ﬂutamide (IC50;FLUT), and n
the  shaping parameter of the Hill curve.
For each conazole the concentration, i.e. benchmark
response (BMR), needed to elicit 25% of the inhibitory
effect on AR activation response caused by ﬂutamide
(BMR25;FLUT) was  calculated by using the formula (2)
below:
BMR25%FLUT “conazole X”
= 10{−[(log((Emax/(y−E0))−1))/n]+log(IC50“conazole X”)} (2)
Subsequently, relative effect potencies were calculated
for each conazole relative to ﬂutamide (REPFLUT) using the
respective BMRs in the following formula (3):
REP “conazole X” =
(
BMR25% FLUT
BMR25% FLUT “conazole X”
)
(3)
2.8. Cytotoxicity
Cell viability of MA-10 and T47D-ARE cells after
exposures was  determined by measuring the capac-
ity  of cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan by the
mitochondrial enzyme succinate dehydrogenase. After
exposure, remaining medium was removed and cells were
incubated with MTT  (1 mg/mL) for 30 min  at 37 ◦C in a
humidiﬁed atmosphere (95%) with 5% CO2. After aspira-
tion, 1 mL  isopropanol was  added at room temperature in
order  to extract the formed blue colored formazan [31].
Absorbance was measured spectrophotometrically at a
wavelength of 595 nm (POLARstar Galaxy, BMG  Labtech
GmbH).
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Fig. 1. Testosterone secretion. Testosterone secretion by MA-10 cells after a 48-h exposure to (1A) the DMSO control, the gonadotropin LH
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.9. Data analysis
All  experiments were performed in triplo and within
ach independent experiment each concentration was
ested  in duplicate (T secretion assays), triplicate (gene
xpression experiments and AR reporter gene assays), or
uadruplicate (ROS assays). The results are depicted as the
ean  of replicates of each experiment with standard error
SEM).  Data calculations were performed using GraphPad
rism 6.0 (GraphPad Software Inc., San Diego, CA, USA).
tatistical signiﬁcance of differences of the mean as com-
ared  to the control was calculated using a two-tailed
npaired Students’ t-test (for single concentrations) or a
ne-way  ANOVA and post hoc Dunnett’s test (for concen-
ration curves). Differences with P < 0.05 were considered
tatistically signiﬁcant.
.  Results
.1. Testosterone secretion inhibition
In order to study the possible effects of conazoles
n male sex steroid production in Leydig cells, basal secretion by MA-10 cells was assessed after a 48-h
xposure to the selected conazoles (10 M).  This concen-
ration did not signiﬁcantly affect MA-10 cell viability (data
ot  shown). Basal T secretion by vehicle-treated controlselected conazoles (10 M);  and (1B) concentration curves of SU10603
IU/mL). Testosterone was measured using a commercially available RIA.
ssed using a Student’s t-test (1A) or a one-way ANOVA test followed by
 0.05). Dotted line (1A) indicates the reference level of the DMSO control.
(0.1%,  v/v DMSO) MA-10 cells was  0.24 ± 0.09 pg/mL. Cells
exposed to the positive control for increased T secretion
(100 M cAMP) showed a signiﬁcant increase of 875-fold
in  secreted T levels in the medium compared to medium
of  vehicle-treated cells (data not shown). Exposure to
the  gonadotropin LH (10 ng/mL = 8.5 IU/mL) caused a sta-
tistically  signiﬁcant increase of 215-fold in T secretion
compared to vehicle-control cells (Fig. 1A). Exposure to the
CYP17  inhibitor SU10603 (1 M)  statistically signiﬁcantly
decreased T secretion by 82% compared to vehicle-treated
cells (Fig. 1A). Of the ten selected conazoles (10 M),  CYPRO
(61%),  FLUS (49%), HEXA (36%), PRO (23%), TEBU (12%), or
TRIT  (44%) statistically signiﬁcantly inhibited T secretion
by  MA-10 cells compared with vehicle-control (Fig. 1A).
To  evaluate the effect of conazoles on LH-induced T
secretion, MA-10 cells were exposed to various concen-
trations of two  widely used conazoles that also showed
marked basal T secretion inhibition, i.e. FLUS and TEBU,
alone  or in combination with LH (10 ng/mL). We  selected
both FLUS and TEBU as representatives of the group of
conazoles tested because of the extensive literature on
developmental and reproductive toxic effects available,
their high usage, as well as their ability to decrease basal
T  secretion. SU10603, FLUS, and TEBU all concentration-
dependently inhibited T secretion (Supplementary Fig.
1).  In combination with LH, SU10603, FLUS, and TEBU
inhibited T secretion with IC50 values of 0.5, 12.4, and
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Fig. 2. Expression of (A) steroidogenic and (B) cholesterol biosynthesis genes. Expression of genes involved in (2A) steroidogenesis or (2B) cholesterol
e select
s of a S
.biosynthesis in MA-10 cells after a 6-h exposure to cAMP (100 M)  or th
as  means ± SEM with N = 3 and n = 3. Signiﬁcance was  assessed by mean
(P  < 0.05). Dotted lines indicate the reference levels of the DMSO controls
2.4 M,  respectively (Fig. 1B). To determine the extent of
inhibition by FLUS and TEBU, the relative effect potency
(REP) of these conazoles was calculated relative to the
known CYP17 inhibitor SU10603 (REPSU10603) according to
the  formula (4):
REPSU10603 “conazole X”  =
( IC50;SU10603
IC50 “conazole X”
)
(4)
This calculation resulted in a REPSU10603 of 0.04 for FLUS
and 0.21 for TEBU.
Supplementary Fig. 1 related to this article can be found,
in  the online version, at doi:10.1016/j.toxrep.2014.05.006.
3.2. Expression of steroidogenic genes
Next, we investigated whether inhibition of T secretion
by  four of the most extensively used conazoles, e.g. CYPRO,
FLUS,  PRO, and TEBU, was a result of altered steroido-
genic gene expression in MA-10 cells. For that, MA-10 cells
were  exposed for 6 h to non-cytotoxic concentrations of the
tested  compounds based on preceding cytotoxicity exper-
iments  (data not shown). The ﬁve genes selected to be
studied encode for the StAR protein, the main cholesterol
transport carrier, as well as for the major enzymes involveded conazoles CYPRO, FLUS, PRO, or TEBU (10 M).  Data are represented
tudent’s t-test. * Signiﬁcantly different from DMSO control-treated cells
in  the testis steroidogenesis route, i.e. Cyp11A1, Cyp17A1,
3-HSD1, and 17-HSD3. Exposure to cAMP (100 M)
resulted in an increase in gene expression of StAR (49-fold),
Cyp11A1 (6-fold), and Cyp17A1 (18-fold) in comparison
with vehicle-treated cells (Fig. 2A). Gene expression of 3-
HSD1  and 17-HSD3 did not signiﬁcantly change upon
cAMP treatment. Exposure to CYPRO, FLUS, PRO, or TEBU
did  not signiﬁcantly affect gene expression of these ﬁve
steroidogenic genes (Fig. 2A).
3.3. Expression of cholesterol biosynthesis genes
Effects of conazoles on cholesterol biosynthesis were
studied since genes involved in “late” steroidogenesis (fol-
lowing  pregnenolone) could not explain the decrease in T
synthesis.  For proper T production, sufﬁcient cholesterol
is  needed as steroid precursor. Gene expression of three
enzymes involved in cholesterol biosynthesis was  deter-
mined,  i.e. cytochrome P450 enzyme 51 (Cyp51), HMG-CoA
reductase (HMG-CoA red), and cytochrome P450 oxidore-
ductase (Por). Exposure to cAMP (100 M)  increased gene
expression of Cyp51 (1.4-fold), HMG-CoA red (1.6-fold),
and Por (1.4-fold) in comparison with vehicle-treated cells
(Fig.  2B). Exposure to PRO increased the expression of
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F 0 cells after a 48-h exposure to each of the ten selected conazoles (100 M). Data
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Table 2
Androgen receptor reporter gene assays outcome expressed as half max-
imal effective or inhibitory concentrations (EC/IC50 [M]), benchmark
response relative to 25% response of ﬂutamide (BMR25%FLUT [M]), and the
relative effect potency (REP) as compared to ﬂutamide of the selected
conazoles. n.a. = not applicable.
Compound EC/IC50 [M]  BMR25%FLUT [M]  REP
T 1.36E−08 n.a. n.a.
FLUT 7.02E−06 1.98E−06 1.00
CYPRO 1.36E−05 5.25E−06 0.38
FLUC n.a. n.a. n.a.
FLUS 1.19E−05 5.49E−07 3.61
HEXA 2.32E−05 7.64E−06 0.26
MYC 7.15E−05 7.06E−05 0.03
PEN 1.71E−05 5.54E−06 0.36
PRO 1.17E−05 9.43E−06 0.21
TEBU 2.55E−05 9.01E−06 0.22ig. 3. ROS production. Reactive oxygen species (ROS) formation by MA-1
re  represented as means ± SEM with N = 3 and n = 4. Signiﬁcance was  asse
ells  (P < 0.05). Dotted line indicates the reference level of the DMSO cont
yp51 (1.7-fold) and HMG-CoA red (1.9-fold) (Fig. 2B).
xposure to TEBU slightly decreased the expression of
he  Por gene (0.8-fold) (Fig. 2B). Other exposures did not
hange  expression of the three cholesterol biosynthesis
enes assessed (Fig. 2B).
.4.  Reactive oxygen species production
To further explore the nature of T secretion inhibition by
A-10  cells after exposure to certain conazole fungicides,
e considered ROS formation as a possible cause for dete-
ioration of Leydig cell function resulting in decreased T
ecretion.  MA-10 cells were exposed to non-cytotoxic con-
entrations (10 nM–100 M)  of the tested compounds. The
ontrol,  rotenone, showed a ROS production of 158 ± 18% of
he  control at 48 h, indicating that the cells were able to pro-
uce  ROS. Only ROS levels in MA-10 cells exposed for 48 h
o  the highest concentration (100 M)  of FLUS, HEXA, PRO,
nd  TEBU were statistically signiﬁcantly increased com-
ared  to time-matched DMSO-treated control cells (Fig. 3).
ncrease  in ROS formation was 1.2, 1.2, 1.3, and 1.4-fold
ompared with vehicle-treated control cells by FLUS, HEXA,
RO,  and TEBU, respectively. The other tested conazoles
CYPRO, FLUC, MYC, PEN, TRIA, and TRIT) did not signiﬁ-
antly change ROS production compared to vehicle-treated
ells (Fig. 3). At lower concentrations (<100 M)  or at ear-
ier  time points (1 and 24 h) no differences in ROS formation
etween vehicle-treated and conazole-treated cells were
bserved (data not shown).
.5.  Inhibition of androgen receptor activation
Because AR activation is a prerequisite for proper sper-
atogenesis, possible effects of conazole exposure on AR
ctivation  were determined using an AR reporter gene
ssay.  T47D-ARE cells were exposed to non-cytotoxic con-
entrations (10 pM to 100 M)  of the tested compounds.
estosterone (T) activated the AR in a concentration-
ependent manner with an EC50 of 13.6 nM (Fig. 4A and
able  2). Exposure to conazoles alone did not signiﬁcantly
ffect AR activation (data not shown). Next, cells were
xposed to 20 nM T in combination with concentration
anges of the selected conazoles (10 pM to 100 M)  or the
R  antagonist ﬂutamide (FLUT; 10 nM to 100 M).  FLUTTRIA 3.21E−05 1.60E−05 0.12
TRIT 1.07E−05 7.80E−06 0.25
concentration-dependently decreased AR activation with
an  IC50 value of 7.0 M (Fig. 4B and Table 2). All cona-
zoles tested, except for FLUC, concentration-dependently
inhibited T-induced AR activation with IC50s ranging from
10.7  to 71.5 M (Fig. 4C–L and Table 2). All of the tested
compounds inhibited T-induced AR activation by maxi-
mally  82%.
In  order to compare the potencies of the tested cona-
zoles to inhibit AR activation, relative effect potencies
(REPs) were calculated using the concentrations where
inhibition of AR activation was  similar to 25% inhibition
by FLUT (BMR25%FLUT).
This leads to the following potency ranking
based on the REP: FLUS > FLUT > CYPRO > PEN > HEXA
>  TRIT > TEBU > PRO > TRIA > MYC  (Table 2).
4. Discussion
We  show here that six of the ten tested conazole fungi-
cides cause a decrease in basal T secretion in murine MA-10
Leydig  cells. In addition, we  demonstrated for two  selected
conazoles a concentration-dependent inhibition of LH-
stimulated T secretion. These effects cannot be adequately
explained by changes in steroidogenic and cholesterol
biosynthesis gene expression nor by increased ROS
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Fig. 4. AR response. AR response measured as relative luminescence units (RLU) as compared to vehicle-treated cells by T47D-ARE cells after a 24-h
 ﬂutami
presente
ifferentexposure  to a concentration curve of (A) testosterone (1 pM to 10 M),  (B)
to  M)  in combination with the EC50 of testosterone (20 nM). Data are re
one-way  ANOVA test followed by Dunnett’s post hoc test. * Signiﬁcantly d
production. Further, nine of the ten tested conazoles
inhibited T-induced AR activation in a reporter gene assay.
These  data show that some conazoles can act as anti-
androgens via two modes of action. Anti-androgenic effects
have  been shown to cause adverse effects in both the
adult as well as the developing male. Without adequate
steroidogenesis leading to sufﬁcient T secretion or by
blockage of the AR response, spermatogenesis cannot be
properly  realized, resulting in abnormal or even absent
sperm production and consequently sub- and/or infertil-
ity  of the adult male. In the fetus, proper T production
and responsiveness are especially important during the
masculinization programming window to ensure correct
development into a phenotypical male [32].
In our study, ﬁve of the tested conazoles, i.e. FLUS,
HEXA, PRO, TEBU, and TRIT, decreased basal T secre-
tion by MA-10 cells by more than 50% compared with
vehicle-treated control cells (Fig. 1A). FLUS and TEBU also
concentration-dependently inhibited T secretion by MA-
10  cells stimulated with LH (Fig. 1B; REPSU10603 = 0.04 and
0.21, respectively), indicating that these compounds can
act  as (in vitro) T secretion inhibitors.
To mechanistically investigate the inhibition of T
secretion by conazoles, we assessed gene expression of
several  enzymes involved in the “late” steroidogenic andde (10 nM to 100 M) or (C–L) each of the ten selected conazoles (100 pM
d as means ± SEM with N = 3 and n = 3. Signiﬁcance was assessed using a
 from vehicle-treated cells (P < 0.05).
cholesterol biosynthesis pathways. However, the cona-
zoles  only inﬂicted minor effects on expression levels of the
selected  genes (Fig. 2), which cannot explain the inhibitory
effects of these conazoles on T secretion in MA-10 Leydig
cells. Makker et al. proposed a role for oxidative stress in
the  occurrence of male infertility [33]. However, levels of
ROS  resulting from exposure to conazoles were only mod-
erately  increased in our study (Fig. 3). Therefore, changes
in  ROS formation were also most likely not the cause of
the  decreased T secretion by MA-10 Leydig cells by the
conazoles used in this study.
Our  results are in accordance with the suggestion from
earlier studies that conazoles show catalytic inhibition
in the steroidogenic pathway [10,19,21]. Previous stud-
ies  indicate that conazoles have the potential to inhibit
mammalian CYP51 enzyme activity via catalytic inhibi-
tion  [9,11]. CYP51 is highly expressed in the testis and
has  an important role in the cholesterol biosynthesis and
ultimately in testosterone production [34,35]. T levels
could also be affected by conazoles via catalytic inhibi-
tion of other steroidogenic cytochrome P450 enzymes.
Several studies have suggested that conazoles can tar-
get  cytochrome P450 enzymes, e.g. imidazoles also inhibit
cytochrome P450 enzymes in human liver, thereby inhibi-
ting  hepatic T metabolism and lowering circulating levels,
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nd lymphoblast cells [20,36,37], This illustrates that cona-
oles  are able to affect the function of multiple CYP
nzymes, also the ones not speciﬁcally within the steroido-
enic  pathway, indicating that this type of enzymes could
e  one of the main targets for endocrine disruption by
onazoles. We  have previously shown that FLUS, ketocona-
ole  (an imidazole), and TEBU inhibit CYP17 activity in
orcine  adrenal cortex microsomes [20]. Furthermore, rat
tudies  showed that hepatic cytochrome P450 activity is
nhibited  in vivo by FLUC and ketoconazole [36]. Previously,
jaerstad et al. stated that the imidazoles are more potent
nhibitors of T secretion by H295R cells than the triazoles
10]. This phenomenon was also seen for decreased T lev-
ls  in fetal rat testes, where PRO showed higher potency
han TEBU [38]. In contrast, our study did not show a
tronger inhibition of T secretion in vitro by the imidaz-
le  PRO compared to the triazole TEBU in murine MA-10
ells  (Fig. 1A). In fact, TEBU is a quite potent inhibitor of T
ecretion  in comparison with the CYP17 inhibitor SU10603
REPSU10603 = 0.21; Fig. 1B). Steroidogenesis in adrenal tis-
ue  occurs predominantly via DHEA whereas in the testes
he  main route for steroidogenesis includes production
f androstenedione [39]. Since H295R cells are fetal-like
drenal cells and MA-10 cells are of testicular origin this
ight  explain the differences in magnitude of response for
onazoles  to affect T secretion found between both cell sys-
ems.  The discordance seen between our in vitro results
nd  the in vivo results might be explained by differential
ffects on aromatase (Cyp19) enzyme activity in the two
ystems  used and a species difference of mouse Leydig
ells versus rat fetal testes. It has been shown that MA-10
ells  do not express the Cyp19 gene and estradiol does not
epress  Cyp17 and 3HSD gene expression [40]. In primary
ultures of Leydig cells from C57BL/6j mice a signiﬁcant
pregulation of Cyp19 gene expression but coordinated
uppression of the LHR, StAR, 3HSD, and Cyp17A1 genes
as  found, which was associated with attenuated andro-
en  production compared to CBA/Lac mice [41]. Further,
stradiol has been found to interfere with in vivo Leydig
ell  function in the rat, thereby lowering CYP17 activity
eading to reduced T biosynthesis [42]. In vitro assays can
e  effectively used to study the effect of chemicals on
 certain speciﬁc mechanism. The shortcoming of these
ssays is that they do not involve an intact organism,
herefore lacking certain physiological feedback mecha-
isms  within the body. A holistic evaluation of data from
 panel of cell-based assays has shown to give a bet-
er  prediction for the ranking of conazoles fungicides for
n  vivo toxicity data [38]. In addition, it has been shown
reviously that exposure to endocrine disruptors exerts
ifferential effects on steroidogenesis in human, mouse,
nd  rat testes, raising concern about the use of rodent
odels and extrapolation of results for human risk assess-
ent  [43]. Possibly, the species-difference in testicular
esponsiveness plays a role in the different potencies of
rochloraz and TEBU in the rat developmental in vivo model
escribed by Dreisig et al. and our in vitro mouse MA-10
tudy [38].
None  of the conazoles showed AR agonistic activity
ut nine out of ten selected conazoles inhibited T-induced
R  activation concentration-dependently in our reporterports 1 (2014) 271–283 281
gene  assay (Fig. 4). The AR antagonistic activity of PRO
and  TEBU is in agreement with a previous study that used
AR-transfected Chinese hamster ovary cells (CHO) [10]. In
our  present study with conazoles, FLUS is the most potent
AR  antagonist with an even higher potency (REP = 3.61)
than  FLUT (REP = 1.00), a well-studied pharmacological AR
antagonist.  All of the selected conazoles contain at least
one  hexacyclic moiety (Table 1), which may  have a func-
tion  comparable to the hexacyclic moiety of T, and thus
may  cause a competitive receptor binding between these
fungicides and androgens [44]. Comparison of the chemi-
cal  structures of these selected conazoles (Table 1) shows
that  FLUS is the only conazole containing an additional
hexacyclic moiety. Possibly, this extra moiety plays a role
in  the AR antagonistic properties of FLUS. Further studies
on  receptor–ligand kinetics are needed to determine the
nature  of these antagonistic interactions.
Besides environmental exposure, individuals can also
be  exposed to conazoles via pharmaceutical application.
FLUC has a pharmacotherapeutic application and treated
patients showed serum levels ranging from 16.3 to 25.8 M
after  oral administration of 200 mg  FLUC per day [45]. It
should  be noted that these blood levels are higher than the
maximum medium concentration of 10 M that caused an
inhibition  of T secretion by MA-10 cells in this study. More-
over,  the fast uptake rate with a Tmax of approximately 2 h
together with the plasma half-life of approximately 30 h
in  humans suggests that signiﬁcant internal exposure to
conazoles  can occur, possibly even resulting in accumu-
lation of these compounds leaving more opportunity for
causing  (adverse) effects, e.g. inhibition of CYP enzymes
[46].
In  addition, because different crops are treated with
different fungicides and conazole mixtures are commer-
cially available, the possibility exists that people may  be
frequently exposed to several conazoles simultaneously.
Mixtures of individual endocrine active compounds,
including conazoles, have been shown to cause additive
effects and antagonism has also been observed [47]. Also
combinations of low doses of multiple conazoles have been
shown  to cause additive effects [48]. An earlier study by
Kjaerstad et al. showed additivity of a mixture containing
two triazoles (propiconazole and TEBU) and one imidaz-
ole  (epoxiconazole) on AR antagonism in AR-transfected
CHO cells as well as T synthesis in H295R cells [49]. Like-
wise,  the triazole propiconazole in combination with other
pesticides showed additive AR activity antagonism [50].
Hence,  low effect concentrations of conazoles, to which
humans are most likely frequently exposed and in mix-
tures,  may  potentially pose a risk for endocrine disruptive
effects. Unfortunately, a proper risk assessment is ham-
pered  by the lack of (systemic) human exposure data.
5.  Conclusion
In summary, this in vitro study shows clear anti-
androgenic effects of several conazole fungicides. These
anti-androgenic effects suggest that potential testicular
toxicity can arise from two mechanisms: inhibition of T
secretion  and AR antagonism. In view of the dual anti-
androgenic effects of the conazoles described here, further
ology R
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studies on the male reprotoxic effects of conazole fungi-
cides  in combination with accurate exposure data are
highly  recommended.
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